Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
Company Information
About this company
Key people
Hyunsu Jung
Chief Executive Officer, Principal Financial Officer, Treasurer, Company Secretary, Director
David Knox
Chief Financial Officer, Treasurer, Secretary
Robert Rubenstein
General Counsel
Happy David Walters
Director
Michael Geltzeiler
Independent Director
Rachel Jacobson
Independent Director
Ellen R. Strahlman
Independent Director
Click to see more
Key facts
- Shares in issue8.47m
- EPICHYPD
- ISINUS30234E2037
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$30.93m
- Employees13
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.